ENT/Head and Neck Cancers

SURVEILLE HPV

National, multicentre, open-label, randomised, phase II study evaluating HPV circulating DNA as biomarker to detect the recurrence, in order to improve post therapeutic surveillance of HPV-driven oropharyngeal cancers.

Open at Paris since : 08/01/2025
Open at Saint-Cloud since : 01/11/2024
Target : Adult
Phase : Phase II

Trial description

Evaluate the negative predictive value (NPV) of circulating HPV DNA (HPVctDNA) at 2 years for detecting recurrence of oropharyngeal cancer (OPC) in patients in complete remission after treatment. The goal is to determine whether the detection of circulating HPV DNA can be used to predict the absence of cancer recurrence.;Improve post-therapeutic surveillance of patients with HPV-driven oropharyngeal cancers by using this circulating DNA as a biomarker to detect early recurrence, enabling faster and more targeted management of the disease.

Url of the trial

Main investigator

JOEY MARTIN

Médecin

Contact